These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38606777)

  • 1. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.
    Babu S; Nicholson KA; Rothstein JD; Swenson A; Sampognaro PJ; Pant P; Macklin EA; Spruill S; Paganoni S; Gendron TF; Prudencio M; Petrucelli L; Nix D; Landrette S; Nkrumah E; Fandrick K; Edwards J; Young PR
    Brain; 2024 Sep; 147(9):2998-3008. PubMed ID: 38606777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
    Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
    Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
    Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
    Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
    Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A;
    Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a sensitive trial-ready poly(GP) CSF biomarker assay for
    Wilson KM; Katona E; Glaria I; Carcolé M; Swift IJ; Sogorb-Esteve A; Heller C; Bouzigues A; Heslegrave AJ; Keshavan A; Knowles K; Patil S; Mohapatra S; Liu Y; Goyal J; Sanchez-Valle R; Laforce RJ; Synofzik M; Rowe JB; Finger E; Vandenberghe R; Butler CR; Gerhard A; Van Swieten JC; Seelaar H; Borroni B; Galimberti D; de Mendonça A; Masellis M; Tartaglia MC; Otto M; Graff C; Ducharme S; Schott JM; Malaspina A; Zetterberg H; Boyanapalli R; Rohrer JD; Isaacs AM;
    J Neurol Neurosurg Psychiatry; 2022 Jul; 93(7):761-771. PubMed ID: 35379698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
    Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
    Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
    Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
    Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
    Genovese MC; Berkowitz M; Conaghan PG; Peterfy C; Davy K; Fisheleva E; Gupta A; Inman D; Janiczek R; Layton M; Mitchell N; Patel J; Roberts A; Saurigny D; Smith JE; Williamson R; Tak PP
    Lancet Rheumatol; 2020 Nov; 2(11):e666-e676. PubMed ID: 38279363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
    Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
    JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.